- Home
- WIMI vs BTAI Comparison
WIMI vs BTAI Comparison
Compare WIMI & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WIMI | BTAI |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 35.6M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WIMI | BTAI |
|---|---|---|
| Price | $1.88 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.33 |
| AVG Volume (30 Days) | 44.3K | ★ 952.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $1.17 |
| 52 Week High | $7.26 | $8.08 |
Technical Indicators
Market Signals| Indicator | WIMI | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 56.40 |
| Support Level | N/A | $1.50 |
| Resistance Level | $3.06 | $2.13 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 60.00 | 83.25 |
Price Performance
Historical ComparisonAbout WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.